

Acetylation of MEK2 and I κ B kinase (IKK) activation loop residues by YopJ inhibits signaling

Rohit Mittal^{†*§}, Sew-Yeu Peak-Chew[†], and Harvey T. McMahon[†]

[†]Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, United Kingdom; and [‡]Department of Biological Sciences, Tata Institute of Fundamental Research, Mumbai 400005, India

Communicated by Richard Henderson, Medical Research Council, Cambridge, United Kingdom, October 13, 2006 (received for review September 15, 2006)

To overcome host defenses, bacterial pathogens of the genus *Yersinia* inject specific effector proteins into colonized mammalian cells. One such virulence factor, YopJ, inhibits the host inflammatory response and induces apoptosis of immune cells by blocking multiple signaling pathways, including the MAPK and NF- κ B pathways. In this study, we show that YopJ exerts its deleterious effects by catalyzing the acetylation of two serine residues in the activation loop of the MAP kinase kinase, MEK2. This covalent modification prevents the phosphorylation of these serine residues that is required for activation of MEK2 and downstream signal propagation. We also show that YopJ causes acetylation of a threonine residue in the activation loop of both the α and β subunits of the NF- κ B pathway kinase, IKK. These results establish a hitherto uncharacterized mode of action for bacterial toxins and suggest the possibility that serine/threonine acetylation may occur even under nonpathogenic conditions and may be a widespread protein modification regulating protein function in eukaryotic cells.

inflammation | MEK

Understanding the mode of action of bacterial toxins has provided insight into the working of mammalian cells especially with regard to signal transduction pathways that impinge upon the activation of the innate immune system (1, 2). Historically, plague has been one of the most devastating diseases to humans, second only to smallpox. The bacillus *Yersinia pestis* is the causative agent of plague, and two other *Yersinia* species, *Yersinia pseudotuberculosis* and *Yersinia enterocolitica*, cause septicemic and gastrointestinal disorders (3). These pathogens inject a bouquet of six effector proteins into the mammalian cell cytosol using a type III secretion apparatus (4). These *Yersinia* outer proteins (Yops) help the pathogen multiply extracellularly in the host by preventing its phagocytosis and by slowing down the onset of the inflammatory response (5). YopE, YopT, and YopO target the Rho family of GTP-binding proteins that control actin cytoskeleton dynamics whereas YopH dephosphorylates focal adhesion proteins, thus inhibiting focal adhesion disassembly. Together, the action of these Yops contributes to the resistance of *Yersinia* to undergo phagocytosis, a process known to require remodeling of the actin cytoskeleton and of focal adhesions. Suppression of phagocytosis enables *Yersinia* to evade the macrophage defense network, thereby allowing them to proliferate in Peyer's patches as extracellular microcolonies. The leucine-rich protein, YopM, has been shown to bind to several host cell kinases, resulting in their activation (6). The remaining outer protein, YopJ (also called YopP in *Y. enterocolitica*) has emerged as an important agent that leads to the reduced host inflammatory response characteristic of *Yersinia* infections (5). Exposure of macrophages to lipopolysaccharide leads to the activation of NF- κ B and of several members of the MAPK family that promote the production of proinflammatory cytokines such as TNF- α . YopJ induces apoptosis in macrophages (7), and it was shown that inhibition of both MAPK and NF- κ B pathways was necessary for this effect (8), suggesting that *Yersinia* might neutralize and eliminate macrophages without

inducing an inflammatory response. Suppression of the inflammatory response is mediated in part by the inhibition of the transcription factor NF- κ B, the activation of which is central to the onset of inflammation. YopJ has been shown to bind directly to many members of the MAPK kinase superfamily and also to IKK (I κ B kinase), preventing signaling through MAP kinases as well as through NF- κ B (9).

Results

Modification of MEK by YopJ. In an effort to understand the biochemical basis of the effects of YopJ on cellular signal transduction, we examined MAP kinase signaling in cultured mammalian cells. The Erk MAP kinase cascade is a three-component cascade in which the MAP kinases, Erk1/2, are activated upon phosphorylation by the MAP kinase kinases, MEK1/2, which are in turn, activated upon phosphorylation by the MAP kinase kinase kinase, Raf (Fig. 1*a*). HeLa cells are a well established system for the study of MAPK signaling and show basal nonphosphorylated Erk1/2 and MEK1/2 levels after serum starvation. Treatment of cells with EGF, phorbol ester (TPA), or the β_2 adrenergic receptor agonist isoproterenol (ISO) leads to transient activation of the MAPK cascade. Treatment with 10 μ M ISO at 37°C causes an activation of Erk and MEK within 5 min with a return to basal unphosphorylated levels by 30 min (see Fig. 4, which is published as supporting information on the PNAS web site). Treatment with EGF and TPA also gave rise to robust activation of Erk1/2 and MEK1/2; however, the return to baseline levels was not complete even 60 min after stimulation (see Fig. 4). It was thus decided to use ISO activation for experiments involving a time-course of MAPK activation.

YopJ has previously been shown to interact with MEK2 and to inhibit its activation (9). We examined the effect of YopJ on MAPK signaling by expressing either WT YopJ or the inactive C172A mutant of YopJ in HeLa cells. MEK1/2 activation after ISO stimulation was inhibited in cells expressing WT YopJ (Fig. 1*b*), whereas cells expressing the inactive C172A mutant of YopJ showed the expected activation of MEK1/2 within 5 min of agonist stimulation, with a return to basal unphosphorylated levels by 30 min. Curiously, when the same cell lysates were examined (Fig. 1*b* Lower) for total MEK1/2 protein levels by using a MEK1/2 antibody (CST9122), no signal was detected in cells expressing WT YopJ, whereas cells expressing the C172A mutant of YopJ showed robust signals for total MEK1/2 protein. This effect of YopJ on the immunodetection of total protein levels was specific for MEK1/2 because total amounts of Erk1/2

Author contributions: R.M. and H.T.M. designed research; and R.M. and S.-Y.P.-C. performed research.

The authors declare no conflict of interest.

Freely available online through the PNAS open access option.

Abbreviations: ISO, isoproterenol; amu, atomic mass unit; I κ B, inhibitor of NF- κ B; IKK, I κ B kinase; MEK1/2, mitogen-activated protein kinase kinase 1/2; Yop, *Yersinia* outer protein.

[§]To whom correspondence should be addressed. E-mail: rohit@mrc-lmb.cam.ac.uk.

© 2006 by The National Academy of Sciences of the USA




Fig. 1. MEK modification by YopJ. (a) The three-component MAPK cascade is an important signaling module that is shared by many signal transduction pathways; the MAPK pathway investigated in this study focuses on the MAP kinase kinases MEK1/2 that, in turn, activate the MAP kinases Erk1/2; this and similar pathways mediate the immediate host response to infection by *Yersinia* species. (b) Immunoblots from HeLa cells transfected with either YopJ-wt or the C172A mutant. Transfected cells were treated with 10 μ M ISO at 37°C for the indicated times. (Upper) In YopJ-expressing cells, there is no signal corresponding to phospho-MEK, indicating that MEK activation is blocked by YopJ; in cells transfected with the C172A mutant of YopJ MEK, activation is clearly seen with a return to baseline levels by 30 min. (Lower) Loss of immunoreactivity with the CST9122 antibody against MEK1/2 in YopJ-wt expressing cells. (c) The block of MEK activation depends on the dosage of transfected YopJ. Indicated amounts (in ng) of plasmid pSFV-YopJ were transfected into a 35 mm dish of HeLa cells. Twenty-four hours after transfection, cells were serum-starved for 6 h and then treated with 10 μ M ISO for 5 min at 37°C. Total lysates were examined by western analysis for phospho MEK1/2 and for total MEK1/2 (using the CST9122 antibody). (d) The loss of MEK signal is specific for the MEK1/2 (CST9122) antibody. Lysates from HeLa cells expressing either WT YopJ or the C172A mutant were immunoblotted by using the indicated antibodies. Whereas the MEK1/2 (CST9122) antibody discriminates between WT and C172A lanes, the other antibodies do not. This observation suggests that expression of active YopJ modifies MEK1/2 in a manner that masks the epitope recognized by the MEK1/2 (CST9122) antibody.

and of other control proteins like beta-actin and calnexin were not observed to be different between YopJ WT and YopJ-C172A cells (Fig. 1d). The effect of YopJ on the activation of MEK1/2 was dose-dependent (Fig. 1c). Consistent with the results of Fig. 1b, the dose dependence of MEK1/2 inhibition correlated precisely with the loss of total MEK1/2 immunosignal as detected by the CST9122 antibody. Taken at face value these results would suggest that expression of YopJ in cells leads to

degradation of MEK1/2 proteins. This interpretation was clearly inadmissible because previous studies had clearly shown that whereas YopJ expression had an effect on the amount of phosphoMEK it had no effect of on total level of MEK proteins (9, 10). We began to suspect that expression of YopJ might be resulting in the masking of the epitope on MEK1/2 recognized by the CST9122 anti-MEK1/2 antibody. We thus probed lysates of HeLa cells expressing WT or inactive YopJ using antibodies directed against other epitopes on MEK1 and MEK2. Because YopJ had been shown to interact with the MAPK kinases MKK3 and MKK4 (9), we also blotted with antibodies against MKK3 and MKK4 to examine whether any of them might show a reduction in total protein levels. By using these antibodies, it was determined that there was equal signal for total MEK protein levels from cells expressing either WT or mutant YopJ proteins (Fig. 1d). Under our experimental conditions, endogenous levels of MKK3 protein could not be detected by using the anti-MKK3 antibody.

The CST9122 MEK1/2 antibody used in Fig. 1 b and c was directed against a 20-aa peptide (conserved in MEK1 and -2) centered about amino acid 220 of MEK1 whereas the MEK1 and MEK2 antibodies used in Fig. 1d were directed against peptides taken from the amino and carboxyl termini of the respective proteins (Cell Signaling Technology). It was thus clear that expression of YopJ was not leading to degradation of MEK1/2 proteins but was causing a masking of the epitope of the anti-MEK1/2 CST9122 antibody that was directed against a peptide near the activation loops of the proteins. This observation was potentially very interesting because it suggested that YopJ expression might prevent activation of MEK1/2 by causing covalent modification of the activation loops of these kinases.

YopJ Leads to Acetylation of MEK2. To elucidate the nature of modification, lysates from YopJ expressing cells were subjected to treatment with phosphatase, reducing agents, mild acid and mild alkali. However, none of these treatments restored the MEK1/2 signal as detected by the CST9122 antibody. Prolonged (5 h) incubation of the lysate in Laemmli Sample Buffer at 95°C did restore the signal, confirming that YopJ was indeed adding some covalent modification to MEK1/2 (data not shown). It must be noted here that given the nature of our readout wherein a loss of signal on a Western blot was diagnostic of the modification, YopJ must certainly be a very highly active enzyme *in vivo* and that most of the MEK molecules in the cell must be modified by YopJ. This effect of expressed YopJ on endogenous MEK1/2 was seen as early as 6 h after transfection of cells (data not shown).

To identify the modification it was decided to isolate MEK from YopJ expressing cells for analysis by mass spectrometry. MEK2 bearing a myc epitope tag at its amino terminus and a hexahistidine tag at the carboxyl terminus was overexpressed in HeLa cells. It was verified from immunoblots by using the MEK1/2 CST9122 antibody that cotransfection of YopJ was sufficient to modify overexpressed myc-MEK2-(His)₆ in a similar fashion to endogenous MEK (data not shown). Myc-MEK2-(His)₆ was prepared by Ni-NTA affinity from lysates of HeLa cells coexpressing YopJ WT or a control plasmid. The prepared samples were analyzed for the presence of modification by Western blots by using anti-myc, anti-MEK2, and the discriminating anti-MEK1/2 CST9122 antibodies (Fig. 2a) and subjected to analysis by mass spectrometry.

Analysis of tryptic digests of the two samples revealed a peptide in MEK2 that was modified by YopJ. Triply charged ions with a mass/charge (*m/z*) ratio of 792.0, corresponding to the amino acid sequence of the activation loop L²¹⁰C*DFGVSGQLIDSMANSFVGTR²³¹ (where C* is carbamidomethylcysteine) was isolated for the control sample and fragmented to confirm the sequence. The corresponding triply




Fig. 3. YopJ modifies IKK α and IKK β . (a) Various proinflammatory stimuli activate the NF- κ B-signaling pathway by activating the I κ B kinase (IKK) complex. IKK activation results in the phosphorylation and subsequent ubiquitin-mediated degradation of I κ B, the inhibitor of NF- κ B. The removal of I κ B results in NF- κ B translocation to the nucleus where it can regulate gene expression. (b) HEK293 cells transfected with YopJ-wt or YopJ-C172A were stimulated with TNF- α . I κ B degradation is slowed down (*Top*) by the expression of YopJ-wt (but not the C172A inactive mutant of YopJ). This effect is due to reduced phosphorylation of I κ B in these cells (*Middle*) caused by inhibition of activation of IKK (*Bottom*) caused by WT YopJ. (c and d) Overexpression of IKK α (c) or IKK β (d) results in their activation in cells expressing inactive YopJ-C172A but this activation is blocked by WT YopJ (*Upper*). Total levels of IKK α and IKK β are not affected by expression of YopJ (*Lower*).

(14) and can be considered to be MAPKK-like molecules in that they are activated by MAPKKK-like molecules (15) and by the fact that the activation loops of MAPKK, IKK α , and IKK β all contain two serine residues (or one serine and one threonine residue) within the sequence SxxxS/T that are phosphorylated by upstream kinases (14). Furthermore, a direct interaction of MAPKKs and IKK β with YopJ has been reported (9).

We investigated the effect of YopJ expression on the NF- κ B pathway by examining the response of YopJ-transfected mammalian cells to the proinflammatory cytokine TNF- α . TNF- α treatment induces a rapid activation of IKK which in turn phosphorylates I κ B leading to the ubiquitination and proteasome-mediated degradation of I κ B. Fig. 3*b* shows that expression of YopJ results in a reduction in this response when HEK293 cells are exposed to TNF- α . Phosphorylation and degradation of I κ B are markedly retarded in cells expressing WT YopJ when compared with cells expressing the inactive C172A mutant of YopJ, which, in turn, correlates well with delayed activation (by phosphorylation) of IKK in these cells (Fig. 3*b* *Bottom*). These results demonstrate that YopJ affects the activation of IKK in mammalian cells.

Overexpression of either IKK α or IKK β is known to result in autophosphorylation of their activation loops leading to activation of their kinase activities (16, 17). We coexpressed Flag-tagged IKK α or Flag-tagged IKK β along with YopJ in mammalian cells. These cells were then examined for their response to stimulation with TNF- α (see Fig. 6, which is published as supporting information on the PNAS web site). It was observed that total levels of I κ B protein were lower in IKK β plus YopJ-wt cells compared with IKK β plus YopJ-C172A cells, whereas no such diminution in I κ B levels was seen in cells overexpressing IKK α (see Fig. 6 *Upper*). This observation is consistent with the fact that activation of IKK β and not IKK α is required for I κ B degradation (12). Furthermore, it suggests that WT YopJ “protects” I κ B from degradation (presumably by affecting IKK activity), whereas inactive YopJ does not. Fig. 3*c* and *d* *Upper* shows that IKK α and IKK β are fully autophosphorylated and activated in cells coexpressing inactive YopJ. Activation of these cells with TNF- α does not lead to any detectable increase in the amount of phosphorylated IKK α or IKK β . Interestingly it is observed (on these same panels) that recognition of expressed IKK α and IKK β by the phospho-specific antibody is abrogated in cells expressing WT YopJ. As control, the total amounts of IKK α and IKK β proteins were verified to be the same in cells expressing either form of YopJ (Fig. 3*c* and *d* *Lower*). This observation immediately suggests that YopJ modifies IKK α and IKK β within the activation loop, most probably by acetylating one or more serine/threonine residues within it.

To identify the site(s) of modification we immunoprecipitated Flag-tagged IKK α and Flag-tagged IKK β from cells coexpressing YopJ. Mass spectrometric analysis (see Fig. 7, which is published as supporting information on the PNAS web site) revealed that both IKK α and IKK β were indeed acetylated on the activation loop. In each case, the modification was on a threonine residue (indicated in bold) located between the two (underlined) phospho-acceptor serine residues (AKDVDQGS**LC(OAc)T**¹⁷⁹SF in IKK α and AKELDQGS**LC(OAc)T**¹⁸⁰SF in IKK β). In addition to Thr-179, IKK α was also found to be acetylated on Ser-119 in the kinase domain and on Thr-722 located near the carboxyl terminus of IKK α . These two residues are, however, not conserved in IKK β and the significance of their modification is not presently clear.

The cysteine residue adjacent to the acetyl-acceptor threonine residue in the activation loops of the catalytic IKK α and IKK β subunits has previously been reported to be covalently modified by cyclopentenone prostaglandins (18) and other thiol-reactive agents (19, 20) resulting in the inhibition of IKK activation.

YopJ-mediated acetylation of the activation loop of the α and β subunits of IKK also prevents activation of the kinase activity of the IKK complex thus preventing phosphorylation of I κ B in response to exposure of cells to TNF- α . These results are consistent with an earlier report (21) wherein it was demonstrated that phosphorylation of the activation loop of IKK β was inhibited in YopJ-expressing mammalian cells. Our results thus provide a mechanistic basis for the observed inhibition of the canonical NF- κ B proinflammatory pathway by YopJ.

Taken together, our results establish that YopJ is an acetyl transferase that catalyses O-acetylation of serine and threonine residues in two important kinases involved in the innate immune response of mammals, thereby inhibiting their activities.

Discussion

Interestingly, the YopJ-like molecule from *Salmonella typhimurium*, AvrA, has been reported to inhibit the NF- κ B pathway (22) and also to inhibit the degradation of β -catenin (23). Phosphorylation of β -catenin occurs within a motif that is highly similar to the phosphorylation motif of I κ B (14) and it has been suggested that IKK α may phosphorylate and regulate the deg-

radation of β -catenin (24). It is thus possible that YopJ-related AvrA may also possess an acetyl transferase activity allowing it to inactivate IKK α thereby exerting its effect on β -catenin degradation.

Whereas acetylation of lysine residues in histones and transcription factors has been widely described there have also been reports of regulated acetylation of nonnuclear proteins (25). Furthermore, it has been suggested that acetylation events may temporally modulate IKK activity (26). Our elucidation of the mechanism of action of the bacterial toxin YopJ proposes the hypothesis that serine/threonine acetylation may be a widespread mode of biochemical regulation of endogenous processes in mammalian cells.

The analgesic and antiinflammatory effects of acetyl salicylic acid (Aspirin) administration are attributed to the transfer of the acetyl group to active site serine residues of cyclooxygenase enzymes resulting in the inhibition of their enzymatic activities. However, the cellular enzymes that (possibly) mediate the acetyl transfer have not been identified. Interestingly, there are by now numerous reports of cyclooxygenase-independent actions of acetyl salicylic acid that impinge primarily upon MAP kinase and NF- κ B-signaling pathways (27, 28). In the light of our results, we speculate that some of these effects might be due to the transfer of acetyl groups to the active sites of MAPKKs/IKKs catalyzed by yet uncharacterized serine/threonine acetyl transferases.

Materials and Methods

Reagents. Isoproterenol and EGF were from Sigma (Dorset, U.K.), TPA was from Cell Signaling Technology (Danvers, MA), TNF- α was from R & D Systems (Minneapolis, MN). Primary antibodies against Erk, phosphoErk, MEK1/2, phosphoMEK1/2, MEK1, MEK2, MKK3, MKK4, I κ B, phosphoI κ B, IKK α , IKK β , and phosphoIKK α/β were from Cell Signaling Technology; primary antibodies against calnexin were from Affinity BioReagents (Golden, CO); and primary antibodies against β -actin were from Abcam (Cambridge, U.K.).

Plasmid Constructs. Plasmids encoding WT YopJ (pSFV-YopJ) and the inactive C172A mutant (pSFV-YopJ-CA) were the kind gifts of K. Orth (University of Texas Southwestern Medical Center, Dallas, TX); pCMV-MEK2 was provided by K.-L. Guan (University of Michigan, Ann Arbor, MI); and pCDNA3-Flag-IKK α and pCMV-Flag-IKK β were kindly provided by D. Ballard (Vanderbilt University Medical Center, Nashville, TN).

pCMV-myc-MEK2-(His) $_6$ coding for MEK2 with a hexahistidine tag at its carboxyl terminus was constructed by amplifying the MEK2 sequence with appropriate primers and ligating into pCMV-myc (a modified pCMV5 plasmid). GST-MEK2 was made by amplifying the coding region of MEK2 and ligating in-frame with GST in the bacterial expression plasmid pGEX6P. (His) $_6$ -YopJ-wt and (His) $_6$ -YopJ-C172A were made by ligating the coding region of YopJ in-frame with the amino-terminal hexahistidine tag of the bacterial expression vector pET28. All constructs used were verified by plasmid sequencing.

Cell Culture and Transfections. HeLa and HEK293 cells were cultured in DMEM (Invitrogen) with 10% FBS. Transfections were typically done with GeneJuice (Novagen) in 35-mm dishes by using 1 μ g of plasmid DNA per dish. Twenty-four hours after transfection, cells were serum-starved for 12–16 h and then stimulated with either ISO (10 μ M) or TNF- α (20 ng/ml) for different times. Cells were harvested in Laemmli Sample Buffer, and lysates were resolved by NuPAGE 4–12% Bis-Tris Gels (Invitrogen). Western Blots were probed with

primary antibodies at a typical dilution of 1:10,000 (except 1:500 for the phosphoIKK α/β antibody) at 4°C for 16 h and then incubated with horseradish peroxidase-linked secondary antibodies at room temperature for an hour followed by ECL (Amersham) detection on Kodak BioMax XAR film.

Mass Spectrometry.

Identification of modification on MEK2. Ten micrograms of the pCMV-myc-MEK2-(His) $_6$ construct was transfected either alone or along with 5 μ g of pSFV-YopJ-wt into each of three 10-cm dishes by using GeneJuice (Novagen). Forty-eight hours after transfection, cells were harvested, and hexahistidine-tagged MEK2 was purified by using NiNTA affinity chromatography. The modified and unmodified MEK2 preparations were resolved by SDS/PAGE and the gel stained by Coomassie blue. Gel slices containing bands corresponding to MEK2 were excised and washed, alkylated, and in-gel digested with trypsin (29). A portion of the extracted tryptic peptides mixture was desalted and concentrated by using a GELoader tip filled with Poros R2 sorbent (PerSeptive Biosystems, Framingham, MA). The bound peptides were eluted with 1 μ l of 60% acetonitrile/3% formic acid directly into a nanospray capillary and then introduced into an API QSTAR pulsar i hybrid quadrupole-time-of-flight mass spectrometer (MDS Sciex, Ontario, Canada). Product ion scans were carried out in positive ion-mode and MS survey scan for peptides from m/z 600 to 1,500 were measured. Selected ions were fragmented by collision-induced dissociation (CID) with nitrogen in the collision cell and spectra of fragment ions produced were recorded in the time-of-flight mass analyzer.

Identification of modification on IKK α and IKK β . Five micrograms of plasmid encoding Flag-tagged IKK α were cotransfected along with 5 μ g of either pSFV-YopJ-wt or pSFV-YopJ-C172A into each of three 10-cm tissue culture dishes. Forty-eight hours after transfection, cells were harvested, and Flag-tagged IKK α protein was immunoprecipitated by using EZview Red Anti-Flag M2 affinity gel (Sigma). Immunoprecipitates were resolved on NuPAGE 4–12% Bis-Tris Gels (Invitrogen). Protein bands corresponding to modified and unmodified IKK α were excised from a Coomassie blue-stained gel, washed, alkylated, and in-gel digested with chymotrypsin.

Peptides from the in-gel digest mixtures were separated by nanoscale liquid chromatography (LC Packings, Amsterdam, The Netherlands) on a reverse-phase C18 column (150 \times 0.075 mm i.d., flow rate 0.15 μ l/min). The eluate was introduced directly into a Q-STAR hybrid tandem mass spectrometer (LC-MS/MS). The spectra were searched against a NCBI nonredundant database with MASCOT MS/MS Ions search (www.matrixscience.com). The modified peptides and acetylation sites were identified by manual inspection of the fragmentation series. The same procedure was used with transfected Flag-IKK β (in place of IKK α) to identify the site of modification in IKK β .

Acetyl Transferase Assays. GST-MEK2 (0.5 μ g) (purified by using standard protocols for GST-tagged protein purification) was incubated with varying amounts (0–200 ng) of (His) $_6$ -YopJ-wt or (His) $_6$ -YopJ-C172A and 80 μ M [1- 14 C]acetyl coenzyme A (56 mCi/mmol; Amersham) (1 Ci = 37 GBq) at 30°C for 40 min. Reaction products were resolved on 4–12% SDS/PAGE gels. Gels were stained with Coomassie blue, destained, soaked in Amplify (Amersham) for 30 min, dried, and subjected to autoradiography for 72 h. For time-course experiments, 0.5 μ g of GST-MEK2 was incubated with 80 ng of (His) $_6$ -YopJ-wt or (His) $_6$ -YopJ-C172A and 80 μ M [1- 14 C]acetyl coenzyme A at 30°C for varying lengths of time. Reactions were stopped by the

addition of SDS/PAGE sample buffer and analyzed as described above.

Note. While this study was being completed, Mukherjee *et al.* (30) reported that YopJ acetylates MKK6 in the activation loop in a manner similar to that reported in this study. Our results confirm that YopJ has acetyl transferase activity, and, taken together, our studies show that, in mammalian cells, this activity inhibits the MAP kinase- and NF- κ B-

signaling pathways by targeting the activation loops of MAP kinase kinases (MKKs) and IKKs.

R.M. thanks Sarada Raghavan, JyotiRanjan Mishra, S. Raghavi, and Veronica Rodrigues for help and cooperation. R.M. acknowledges grants from the British Council, India, and from The Royal Society (International Incoming Fellowship) and is currently supported by the Medical Research Council, U.K. (Career Development Fellowship).

1. Galan JE, Cossart P (2005) *Curr Opin Microbiol* 8:1–3.
2. Aktories K, Barbieri JT (2005) *Nat Rev Microbiol* 3:397–410.
3. Cornelis GR (2000) *Proc Natl Acad Sci USA* 97:8778–8783.
4. Galan JE, Collmer A (1999) *Science* 284:1322–1328.
5. Viboud GI, Bliska JB (2005) *Annu Rev Microbiol* 59:69–89.
6. McDonald C, Vaccratsis PO, Bliska JB, Dixon JE (2003) *J Biol Chem* 278:18514–18523.
7. Monack DM, Meccas J, Ghori N, Falkow S (1997) *Proc Natl Acad Sci USA* 94:10385–10390.
8. Zhang Y, Ting AT, Marcu KB, Bliska JB (2005) *J Immunol* 174:7939–7949.
9. Orth K, Palmer LE, Bao ZQ, Stewart S, Rudolph AE, Bliska JB, Dixon JE (1999) *Science* 285:1920–1923.
10. Orth K, Xu Z, Mudgett MB, Bao ZQ, Palmer LE, Bliska JB, Mangel WF, Staskawicz B, Dixon JE (2000) *Science* 290:1594–1597.
11. Schesser K, Spiik AK, Dukuzumuremyi JM, Neurath MF, Pettersson S, Wolf-Watz H (1998) *Mol Microbiol* 28:1067–1079.
12. Chen ZJ (2005) *Nat Cell Biol* 7:758–765.
13. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, *et al.* (2001) *Science* 293:1495–1499.
14. Karin M, Ben-Neriah Y (2000) *Annu Rev Immunol* 18:621–663.
15. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (2001) *Nature* 412:346–351.
16. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) *Cell* 91:243–252.
17. Zandi E, Chen Y, Karin M (1998) *Science* 281:1360–1363.
18. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG (2000) *Nature* 403:103–108.
19. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M (2000) *J Biol Chem* 275:36062–36066.
20. Jeon KI, Byun MS, Jue DM (2003) *Exp Mol Med* 35:61–66.
21. Carter RS, Pennington KN, Ungurait BJ, Arrate P, Ballard DW (2003) *J Biol Chem* 278:48903–48906.
22. Collier-Hyams LS, Zeng H, Sun J, Tomlinson AD, Bao ZQ, Chen H, Madara JL, Orth K, Neish AS (2002) *J Immunol* 169:2846–2850.
23. Sun J, Hobert ME, Rao AS, Neish AS, Madara JL (2004) *Am J Physiol Gastrointest Liver Physiol* 287:G220–227.
24. Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hulit J, Sakamaki T, Fu M, Ben-Ze'ev A, *et al.* (2003) *Mol Biol Cell* 14:585–599.
25. Kouzarides T (2000) *EMBO J* 19:1176–1179.
26. Quivy V, Van Lint C (2004) *Biochem Pharmacol* 68:1221–1229.
27. Tegeder I, Pfeilschifter J, Geisslinger G (2001) *FASEB J* 15:2057–2072.
28. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J (2003) *J Biol Chem* 278:24944–24950.
29. Shevchenko A, Wilm M, Vorm O, Mann M (1996) *Anal Chem* 68:850–858.
30. Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ, Orth K (2006) *Science* 312:1211–1214.